AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02712983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP dose regimen
Study NCT02712983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP and placebo
Description: TIP and inhaled placebo dose regimen
Study NCT02712983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo dose regimen
Study NCT02815657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
Study NCT02815657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
Study NCT01457014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation auto
Description: Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
Study NCT01457014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure
Study NCT01457014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation manual
Description: servo ventilation titrated in manual mode
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT03922594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis
Study NCT00187876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Biocleanse, surgical
Description: The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
Study NCT01384253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ²¹²Pb-TCMC-Trastuzumab
Description: The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
Study NCT01384253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg.
Study NCT02670083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT02670083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study NCT01786798 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transvaginal sonography
Description: Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern
Study NCT02870582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: treatment drug
Study NCT02870582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Best support treatment
Study NCT01439191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized anti-HER2 antibody
Description: Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
Study NCT01439191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
Study NCT02329353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 Lozenges
Description: Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT03710538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack beverage
Description: Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
Study NCT03710538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3min walk at 60% VO2max every 30 minutes,(x5)
Study NCT04506021 — intervention group
Intervention type: DRUG
Intervention: Bicarbonate Ringer's solution
Description: According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
Study NCT04506021 — intervention group
Intervention type: DRUG
Intervention: Other Crystalloid
Description: According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
Study NCT00081484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa or beta
Description: iv or sc, as prescribed
Study NCT00081484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
Study NCT00628784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
Study NCT03408418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Description: The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
Study NCT03241277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal treatment
Description: Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
Study NCT00628784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic spray cryotherapy
Description: After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
Study NCT00436683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermagate
Description: Film coated tablet 500mg
Study NCT00436683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: tablet 800mg
Study NCT03529916 — intervention group
Intervention type: OTHER
Intervention: isolation of endothelial cells precursors in blood
Description: Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT01318694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALV Placebo
Description: ALV placebo soft gel capsules administered orally
Study NCT03802994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23 valent pneumococcal polysaccharide vaccine
Description: FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
Study NCT03802994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent conjugated pneumococcal vaccine
Description: FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
Study NCT03241277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal treatment
Description: Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
Study NCT02227069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Study NCT02227069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M518101 Vehicle
Study NCT02227069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium lauryl sulfate
Study NCT02227069 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Study NCT00322452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral tablet
Study NCT00322452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV
Study NCT00322452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV
Study NCT01961856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Ticagrelor
Description: Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
Study NCT01961856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading dose
Study NCT03576404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Pharmacist Care
Description: A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
Study NCT03831295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody BMS 986178
Description: Given IT or IV
Study NCT03831295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given IT
Study NCT03689491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
Study NCT03689491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
Study NCT03689491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual feedback training
Description: Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
Study NCT03689491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: visual feedback training
Description: Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
Study NCT03689491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: 30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
Study NCT03044119 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant with PRFM
Description: placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
Study NCT03044119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dental Implant with PRFM and PBMSCs
Description: placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle
Study NCT01357161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: carboplatin, IV infusion on Day 1 of each 3-week cycle
Study NCT04234646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) 2.0 Checklist
Description: The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
Study NCT04234646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-on-one Patient Navigation (PN)
Description: The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
Study NCT01335893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
Study NCT04473274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Receive pioglitazone 15mg - 30mg daily
Study NCT04265157 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique surgical occlusion
Description: Occlusion of hepatoduodenal ligament by clamp or occlusive bands
Study NCT02910401 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus (GMP RV16 HRV-16)
Description: 300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
Study NCT00992199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, Fluorouracil
Description: cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
Study NCT04544930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapist-guided
Description: Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
Study NCT03631004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: olanzapine 10 mg is given before surgery
Study NCT03631004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine 10 mg is given before surgery
Study NCT01331837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
Study NCT01331837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
Study NCT04565444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: * Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring
Study NCT04565444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone + Protein
Description: * Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)
Study NCT04565444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: * Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)
Study NCT01708265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting
Description: In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
Study NCT01708265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early mitral valve repair
Description: Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
Study NCT04008641 — intervention group
Intervention type: OTHER
Intervention: Pediatric consultation's survey
Description: Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
Study NCT04148196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Description: The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
Study NCT00721760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00721760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00721760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection
Study NCT00721760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection